Oasis Pharmaceuticals
Publicly observedLexington, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Lexington | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Oasis Pharmaceuticals | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | F2ZWBFV5NZ86 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant15 Sept 2025Publicly observed
NIH SBIR/STTR award: Development of PAR2 Pepducins for the Treatment of COPD
USD 468,369.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Feb 2023Publicly observed
NIH SBIR/STTR award: Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy
USD 50,000.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.